J.T. Chambers

483 total citations
23 papers, 358 citations indexed

About

J.T. Chambers is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Molecular Biology. According to data from OpenAlex, J.T. Chambers has authored 23 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Reproductive Medicine, 8 papers in Obstetrics and Gynecology and 5 papers in Molecular Biology. Recurrent topics in J.T. Chambers's work include Ovarian cancer diagnosis and treatment (11 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Uterine Myomas and Treatments (5 papers). J.T. Chambers is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Uterine Myomas and Treatments (5 papers). J.T. Chambers collaborates with scholars based in United States and Ireland. J.T. Chambers's co-authors include M. L. Carcangiu, Lee K. Tan, Suzanne K. Chambers, E.I. Kohorn, Peter E. Schwartz, Peter E. Schwartz, Leslie M. Scoutt, Frederick R. Long, Stuart D. Flynn and Thomas P. Duffy and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Radiology.

In The Last Decade

J.T. Chambers

23 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.T. Chambers United States 10 221 205 60 49 41 23 358
David L. Marchetti United States 12 171 0.8× 138 0.7× 68 1.1× 75 1.5× 40 1.0× 12 293
Masashi Nishiya Japan 9 203 0.9× 225 1.1× 78 1.3× 54 1.1× 97 2.4× 18 388
Ergin Bengisu Türkiye 9 181 0.8× 143 0.7× 56 0.9× 33 0.7× 63 1.5× 25 373
Nilsa C. Ramirez United States 9 179 0.8× 243 1.2× 58 1.0× 85 1.7× 45 1.1× 12 368
Allan J. Jacobs United States 9 180 0.8× 139 0.7× 100 1.7× 59 1.2× 39 1.0× 19 321
Piotr Sobiczewski Poland 11 161 0.7× 153 0.7× 62 1.0× 37 0.8× 50 1.2× 35 269
Peter R. Dottino United States 10 151 0.7× 108 0.5× 114 1.9× 66 1.3× 27 0.7× 30 282
Madeline Mason United States 3 205 0.9× 143 0.7× 105 1.8× 30 0.6× 26 0.6× 8 287
H.E. Averette United States 7 137 0.6× 219 1.1× 75 1.3× 53 1.1× 22 0.5× 11 332
M Abrate Italy 11 99 0.4× 132 0.6× 46 0.8× 49 1.0× 102 2.5× 25 368

Countries citing papers authored by J.T. Chambers

Since Specialization
Citations

This map shows the geographic impact of J.T. Chambers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.T. Chambers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.T. Chambers more than expected).

Fields of papers citing papers by J.T. Chambers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.T. Chambers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.T. Chambers. The network helps show where J.T. Chambers may publish in the future.

Co-authorship network of co-authors of J.T. Chambers

This figure shows the co-authorship network connecting the top 25 collaborators of J.T. Chambers. A scholar is included among the top collaborators of J.T. Chambers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.T. Chambers. J.T. Chambers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chambers, J.T., et al.. (2005). Endometrial adenocarcinoma presenting in a premenopausal patient with tuberous sclerosis. Journal of Intellectual Disability Research. 49(6). 463–465. 3 indexed citations
2.
Chambers, J.T., Thomas Rutherford, Peter E. Schwartz, et al.. (2003). A pilot study of topotecan in the treatment of serous carcinoma of the uterus. International Journal of Gynecological Cancer. 13(2). 216–222. 6 indexed citations
3.
Pal, Lubna, Vinita Parkash, & J.T. Chambers. (2003). Eosinophilia and Uterine Leiomyosarcoma. Obstetrics and Gynecology. 101(Supplement). 1130–1132. 2 indexed citations
4.
Chambers, J.T., et al.. (2002). Low prevalence of abnormal cervical cytology in an institutionalized population with intellectual disability. Journal of Intellectual Disability Research. 46(7). 569–574. 12 indexed citations
5.
Odunsi, Kunle, E.I. Kohorn, Vinita Parkash, et al.. (1998). Necrosis of Myometrial Choriocarcinoma with Fulminating Sepsis Complicating Chemotherapy for Trophoblastic Tumor. Gynecologic Oncology. 70(1). 100–104. 3 indexed citations
6.
Chambers, Suzanne K., J.T. Chambers, Carol A. Davis, et al.. (1997). Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.. Journal of Clinical Oncology. 15(5). 1945–1952. 12 indexed citations
7.
Carcangiu, M. L., Lee K. Tan, & J.T. Chambers. (1997). Stage IA Uterine Serous Carcinoma. The American Journal of Surgical Pathology. 21(12). 1507–1514. 89 indexed citations
8.
Cass, Ilana, Ephraim Resnik, J.T. Chambers, et al.. (1996). Combination Chemotherapy with Etoposide, Cisplatin, and Doxorubicin in Mixed Müllerian Tumors of the Adnexa. Gynecologic Oncology. 61(3). 309–314. 11 indexed citations
9.
Resnik, Ephraim, Suzanne K. Chambers, M.L. Carcangiu, et al.. (1996). Malignant uterine smooth muscle tumors: Role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy. Journal of Surgical Oncology. 63(3). 145–147. 3 indexed citations
10.
Chambers, Suzanne K., et al.. (1996). Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.. PubMed. 2(10). 1699–704. 9 indexed citations
11.
Resnik, Ephraim, Suzanne K. Chambers, M.L. Carcangiu, et al.. (1995). A Phase II Study of Etoposide, Cisplatin, and Doxorubicin Chemotherapy in Mixed Müllerian Tumors (MMT) of the Uterus. Gynecologic Oncology. 56(3). 370–375. 23 indexed citations
12.
Scoutt, Leslie M., Stuart D. Flynn, Frederick R. Long, et al.. (1995). Clinical stage I endometrial carcinoma: pitfalls in preoperative assessment with MR imaging. Work in progress.. Radiology. 194(2). 567–572. 76 indexed citations
13.
Price, Fredric V., S. Chambers, J.T. Chambers, et al.. (1993). Colony‐stimulating factor‐1 in primary ascites of ovarian cancer is a significant predictor of survival. International Journal of Gynecology & Obstetrics. 43(1). 98–98. 1 indexed citations
14.
Hayden, Cheryl L., et al.. (1992). Prognostic variables for ovarian cancer. Gynecologic Oncology. 45(1). 105–105. 2 indexed citations
15.
Chambers, J.T. & Suzanne K. Chambers. (1992). 92113679 Endometrial sampling: When? Where? Why? With what?. Maturitas. 15(2). 167–167. 4 indexed citations
16.
Chambers, Suzanne K., et al.. (1989). Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer. 64(12). 2459–2461. 33 indexed citations
17.
Carcangiu, Maria Luisa, et al.. (1989). Use ofCA-125, NB/70K, and LSA in monitoring uterine papillary serous carcinoma. Gynecologic Oncology. 32(1). 122–122. 4 indexed citations
18.
Schwartz, Peter E., J.T. Chambers, E.I. Kohorn, et al.. (1989). Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer: A prospective randomized trial. Gynecologic Oncology. 32(1). 100–100. 1 indexed citations
19.
Chambers, J.T., et al.. (1989). Evaluation of the role of second‐look surgery in ovarian cancer. International Journal of Gynecology & Obstetrics. 28(3). 317–318. 44 indexed citations
20.
Cunningham, S. K., et al.. (1988). Optimisation of total urinary aldosterone estimation: Comparison with other laboratory methods for assessment of mineralocorticoid status. Journal of Steroid Biochemistry. 31(1). 125–130. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David L. Marchetti Breakdown of academic impact, for papers by Masashi Nishiya Breakdown of academic impact, for papers by Ergin Bengisu Breakdown of academic impact, for papers by Nilsa C. Ramirez Breakdown of academic impact, for papers by Allan J. Jacobs Breakdown of academic impact, for papers by Piotr Sobiczewski Breakdown of academic impact, for papers by Peter R. Dottino Breakdown of academic impact, for papers by Madeline Mason Breakdown of academic impact, for papers by H.E. Averette Breakdown of academic impact, for papers by M Abrate
Rankless by CCL
2026